Axsome Therapeutics, Inc. (NASDAQ:AXSM) General Counsel Hunter R. Murdock Sells 6,014 Shares

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) General Counsel Hunter R. Murdock sold 6,014 shares of the stock in a transaction on Monday, June 23rd. The stock was sold at an average price of $100.12, for a total value of $602,121.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Hunter R. Murdock also recently made the following trade(s):

• On Friday, June 20th, Hunter R. Murdock sold 7,500 shares of Axsome Therapeutics stock. The stock was sold at an average price of $102.47, for a total transaction of $768,525.00.
• On Tuesday, June 17th, Hunter R. Murdock sold 7,500 shares of Axsome Therapeutics stock. The shares were sold at an average price of $100.26, for a total transaction of $751,950.00.

Axsome Therapeutics Trading Up 1.0%

Shares of AXSM stock traded up $0.96 on Monday, reaching $101.65. 638,409 shares of the company's stock were exchanged, compared to its average volume of 677,733. Axsome Therapeutics, Inc. has a 52 week low of $72.21 and a 52 week high of $139.13. The stock has a market capitalization of $5.01 billion, a PE ratio of -17.62 and a beta of 0.48. The company's fifty day simple moving average is $106.72 and its 200 day simple moving average is $107.16. The company has a current ratio of 2.03, a quick ratio of 1.96 and a debt-to-equity ratio of 3.48.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Morgan Stanley increased their price objective on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Cantor Fitzgerald raised shares of Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Wells Fargo & Company reaffirmed an "overweight" rating and set a $165.00 price objective (up from $160.00) on shares of Axsome Therapeutics in a research report on Tuesday, May 6th. Needham & Company LLC reduced their price target on Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating on the stock in a research note on Monday, June 9th. Finally, Robert W. Baird upped their target price on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $172.33.

Institutional Investors Weigh In On Axsome Therapeutics

Institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Axsome Therapeutics during the first quarter worth about $25,000. NBC Securities Inc. acquired a new stake in Axsome Therapeutics during the first quarter worth about $31,000. Quantbot Technologies LP acquired a new position in shares of Axsome Therapeutics in the 1st quarter valued at $31,000. AlphaQuest LLC acquired a new stake in shares of Axsome Therapeutics during the 1st quarter valued at about $38,000. Finally, Neo Ivy Capital Management purchased a new stake in shares of Axsome Therapeutics in the first quarter valued at approximately $41,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.